Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients.

Ravindranath MH, Selvan SR, Terasaki PI.

J Immunotoxicol. 2012 Jul-Sep;9(3):282-91. doi: 10.3109/1547691X.2011.645582. Epub 2012 Jan 30.

PMID:
22283601
2.

Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients.

Ravindranath MH, Pham T, Ozawa M, Terasaki PI.

Int Immunol. 2012 Jan;24(1):43-57. doi: 10.1093/intimm/dxr094. Epub 2011 Dec 20.

PMID:
22190577
3.

Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera.

Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI.

J Immunol. 2010 Aug 1;185(3):1935-48. doi: 10.4049/jimmunol.1000424. Epub 2010 Jul 7.

4.

Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles.

Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S.

Blood. 2013 Mar 14;121(11):2013-28. doi: 10.1182/blood-2012-08-447771. Epub 2013 Jan 10.

5.

HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies.

Ravindranath MH, Taniguchi M, Chen CW, Ozawa M, Kaneku H, El-Awar N, Cai J, Terasaki PI.

Mol Immunol. 2010 Feb;47(5):1121-31. doi: 10.1016/j.molimm.2009.10.024. Epub 2009 Nov 26.

PMID:
19944464
6.

Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies.

Ravindranath MH, Pham T, El-Awar N, Kaneku H, Terasaki PI.

Mol Immunol. 2011 Jan;48(4):423-30. doi: 10.1016/j.molimm.2010.09.011. Epub 2010 Dec 9.

PMID:
21145594
7.

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.

Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF.

Cancer. 1997 Aug 1;80(3):401-12. Erratum in: Cancer 1999 Oct 1;86(7):1380.

PMID:
9241074
8.

Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.

LeMay LG, Kan-Mitchell J, Goedegebuure P, Harel W, Mitchell MS.

Cancer Immunol Immunother. 1993 Aug;37(3):187-94.

PMID:
8101473
9.

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.

Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.

PMID:
9815296
10.

Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.

Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG.

Cancer Res. 2004 Aug 1;64(15):5481-8.

11.

Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept.

Ravindranath MH, Zhu D, Pham T, Jucaud V, Hopfield J, Kawakita S, Terasaki PI.

Clin Transpl. 2013:293-305. Review.

PMID:
25095521
12.

Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Morton DL.

Cancer Immunol Immunother. 1992;34(6):419-23.

PMID:
1373343
13.

Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Foshag LJ, Morton DL.

Cell Immunol. 1992 Feb;139(2):411-25.

PMID:
1733512
14.

Identification of epitopes and immunodominant regions on the MICA protein defined by alloantibodies from kidney transplant patients.

Suárez-Alvarez B, Alonso-Arias R, Bravo-Mendoza C, López-Vázquez A, Ortega T, Baltar JM, Coto E, Ortega F, López-Larrea C.

Transplantation. 2009 Aug 15;88(3 Suppl):S68-77. doi: 10.1097/TP.0b013e3181afeb7a.

PMID:
19667965
15.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

16.

Immunodominance across HLA polymorphism: implications for cancer immunotherapy.

Kim CJ, Parkinson DR, Marincola F.

J Immunother. 1998 Jan;21(1):1-16. Review.

PMID:
9456431
18.

The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes.

Ravindranath MH, Terasaki PI, Pham T, Jucaud V.

Monoclon Antib Immunodiagn Immunother. 2015 Jun;34(3):135-53. doi: 10.1089/mab.2014.0096.

PMID:
26090591
20.

Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.

Kammula US, Marincola FM, Rosenberg SA.

J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44.

PMID:
10944556

Supplemental Content

Support Center